Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]
News [3134]
Articles [127]
Editorials [3]
Conferences [120]
elearning [13]
Ibrutinib significantly delays disease progression and extends survival in...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Ibrutinib significantly delays disease progression and extends survival in...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Emerging pathways in immunotherapy
Prof Christopher Höller - Medical University of Vienna, Vienna, Austria
Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )
20 May 2014
Myeloma genomics and Immuno-oncology
Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio...
Myeloma genomics and Immuno-oncology ( Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo )
15 May 2014
Novel targets and immune based therapy in myeloma
Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San...
Novel targets and immune based therapy in myeloma ( Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel )
15 May 2014
Upcoming trends in myeloma therapy
Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson
Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )
15 May 2014
Recent advances in mantle cell lymphoma: Expert panel discussion
Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele...
Recent advances in mantle cell lymphoma: Expert panel discussion ( Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci )
13 May 2014
Idelalisib shows promising results in patients with double refractory indolent...
Dr Andrew Davies - Southampton General Hospital, Southampton, UK;
Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )
9 May 2014
Rituximab versus idelalisib in refractory CLL
Prof John Gribben - Queen Mary University London, London, UK; Prof Peter...
Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )
9 May 2014
New agents extend progression-free survival in double refractory myeloma
Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta...
New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )
8 May 2014
Aspirin analogues developed for anti-cancer effects on leukaemia
Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK
Aspirin analogues developed for anti-cancer effects on leukaemia ( Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK )
8 May 2014
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic...
Dr Valentin Goede - University of Cologne, Cologne, Germany
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )
8 May 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation